Cited by 19Multiple Sclerosis Research StudiesNeuroinflammation and Neurodegeneration MechanismsMicroRNA in disease regulation

MiR-124 and MiR-155 as Therapeutic Targets in Microglia-Mediated Inflammation in Multiple Sclerosis

Open access
Asl, Elmira Roshani, Hosseini, Seyedeh Elnaz, Tahmasebi, Fatemeh, Bolandi, Nadia, Barati, Shirin·2025·Cellular and Molecular Neurobiology

Abstract

Multiple sclerosis (MS) is a chronic inflammatory disease associated with demyelination and microglial activation. Significant progress has recently been made in the development of strategies to treat MS with a focus on microglial cells. In response to injury, microglia, a population of mononuclear phagocytic cells, change from quiescent to activated. M1 microglia produce pro-inflammatory cytokines that cause additional injury, thus they are considered neurotoxic microglia. M2 microglia release anti-inflammatory factors that lead to the suppression of inflammatory responses; therefore, they have a neurotrophic phenotype. The balance between M1 and M2 phenotypes is important for nerve recovery. In neurodegenerative diseases, activated microglia are excessively shifted toward M1 or neurotoxic phenotype due to microRNA (miRNA) dysregulation. The miRNA as a class of non-coding RNAs, control the neuroinflammatory process by activation of microglia. The miR-124 is partly responsible for suppressing the neuroprotective and inflammatory processes by preventing microglia activation. Meanwhile, the microRNA 155, which is induced by pro-inflammatory agents in microglia, promotes the inflammatory process. Several studies have shown that in MS pathogenesis, miR-124 as an anti-inflammatory marker is significantly downregulated, while miR-155 shows an increase. In this study, we will investigate the role of miR-124 and miR-155 in the activation and alteration of microglial phenotype. Finding the relationship between microRNAs and glial cells and inflammation in MS may be used as a therapeutic method to reduce the symptoms in MS patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10571-025-01578-6

Cites

166 of 166 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Goldenberg MM (2012) Multiple sclerosis review. Pharm Therap. 37(3):175

Cited by

Sorted by citations

Authors
Asl, E. R., Hosseini, S. E., Tahmasebi, F., Bolandi, N., & Barati, S.
Affiliations
  • Saveh University of Medical Sciences (IR)
  • Shahid Beheshti University (IR)
Corresponding author
Barati, Shirin
Venue
Cellular and Molecular Neurobiology
Published
2025-07-07
Volume
45
Issue
1
Pages
63-63
ISSN
  • 0272-4340 (ISSN-L)
  • 1573-6830
OpenAlex
W4412068824
Cited by
19
References
166
Citations by year
2026: 14 · 2025: 5
FWCI
3.12
Type
journal article
Language
en
Open access
Locations
  • Cellular and Molecular Neurobiology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Çukurova Üniversitesi
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
Keywords
multiple sclerosis, microglia, microRNA, miR-124, miR-155, microglial activation, M1/M2 microglial polarization, neuroinflammation, demyelination, therapeutic target, microRNA dysregulation
MeSH terms
Animals, Humans, Inflammation, Multiple Sclerosis, Microglia, MicroRNAs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review